Intractable Epilepsy denials in California external review

In the California DMHC record, independent physician reviewers decided 16 published external-review cases involving intractable epilepsyand overturned the plan’s denial in 93.8%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
16
2006–2025
Overturned
93.8%
15 denials reversed

Most-fought treatments for intractable epilepsy

What insurers denied — and how those fights ended.
CategoryDecisionsOverturned
Magnetoencephalography3
100%

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
11
100%
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
5
80%
Typical time to a decision
15 days
Most land between 6 and 21 days
Handled as urgent
43.8%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Physician 1: The patient is a 21-year-old female who was diagnosed with epilepsy ten years ago. She has frequent seizure activity of various types and medications have not brought her seizures under control. The patient is requesting authorization for MEG as part of a workup for possible epilepsy surgery. The Health Plan considers the diagnostic proceed investigational and has denied the requested authorization.Magnetoencephalograpy (MEG) remains an experimental and investigational technique. At this time, the ability of MEG to identify foci of seizure activity remains unproven. There is no substantial proof of its effectiveness for the treatment of intractable epilepsy. Thus, MEG is not likely to be more efficacious than standard imaging techniques.
Experimental/Investigational · 2006 · IMR EI06-5840
Physician 1: The patient is a 47-year-old female who has experienced intractable seizures since childhood. A large number of anti-seizure medications have been tried without significant improvement. The patient is contemplating neurosurgery to ablate the seizure focus. Prior to surgery, it has been recommended that she undergo magnetoencephalography (MEG). The Health Plan has denied authorization for the requested diagnostic procedure on the basis that it remains investigational at this time.Review of the medical literature reveals that the clinical usefulness of MEG in this setting has not yet been established. MEG is a relatively new diagnostic procedure and has not been fully refined. To date, the success rate has not been impressive. As such, it is not likely that MEG will have clinical value in the evaluation of this patient’s long-standing seizure problem.
Experimental/Investigational · 2006 · IMR EI06-5169

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for the use of a power standing feature for the already approved powered wheelchair. The records indicate that this patient presents with complex intractable epilepsy, developmental delay, cellulitis, neuropathy, mild ataxia, and paraplegia with hypotonia. The patient has been noted to currently require a manual wheelchair for mobility that a caregiver must propel. The medical records lack sufficient documentation regarding the patient’s current level of function in terms of performing daily activities and mobility, as well as physical examination findings, including graded motor strength and range of motion of the upper and lower extremities.
Medical Necessity · 2025 · IMR MN25-44649

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving intractable epilepsy, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for intractable epilepsy? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9